Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Reddy's has informed the stock exchanges that the Phase III TACTI-004 trial of Eftilagimod Alfa (efti) in first-line non-small cell lung cancer has been recommended for discontinuation by the Independent Data Monitoring Committee (IDMC) following a planned interim futility analysis. The drug was licensed by Dr. Reddy's wholly-owned subsidiary (Dr. Reddy's SA) from France-based Immutep SAS in December 2025, for development and commercialization in countries outside North America, Europe, Japan, and Greater China. Immutep will now wind down the study with appropriate patient follow-up and site close-out, and is conducting a comprehensive data review. Dr. Reddy's clarifies that it has only made the upfront payment to Immutep so far and is engaging with Immutep on the way forward.
This is a negative outcome for the licensing deal, as the key Phase III asset has failed futility analysis, reducing its commercial potential. However, the direct financial hit appears limited since only the upfront payment has been made, and the impact on Dr. Reddy's overall business and financials is likely to be modest.